MK-677

Mechanism of Action

MK-677 (ibutamoren mesylate, developmental code L-163,191) is a small-molecule, orally bioavailable ghrelin receptor agonist that mimics the stimulatory actions of acylated ghrelin on growth hormone (GH) secretion. Its molecular weight of approximately 624 Da and its spiroindane scaffold distinguish it structurally from both endogenous ghrelin (a 28-amino-acid acylated peptide) and from peptide secretagogues such as GHRP-6 or hexarelin. This small-molecule architecture is the central pharmacological advantage of MK-677: it survives first-pass hepatic metabolism and gastrointestinal peptidase activity, making once-daily oral dosing practically feasible — a property no injectable GH secretagogue peptide possesses.

The primary molecular target is the growth hormone secretagogue receptor type 1a (GHS-R1a), a Gαq-coupled GPCR expressed most densely in the hypothalamus (arcuate nucleus, ventromedial nucleus), anterior pituitary somatotrophs, and vagal nerve terminals. GHS-R1a is constitutively active at approximately 50% of its maximum signaling capacity in the absence of ligand — an unusually high basal activity for a GPCR — which contributes to the broad range of physiological effects attributable to this receptor. When MK-677 binds GHS-R1a, it drives full agonist Gαq activation, stimulating PLCβ, IP₃-mediated calcium release, and PKC activation. In hypothalamic cells, this increases somatostatin neuron inhibition and enhances GHRH (growth hormone-releasing hormone) synthesis. In pituitary somatotrophs, direct GHS-R1a activation amplifies the GH secretory response to endogenous GHRH pulses, producing a synergistic effect that generates GH pulses of substantially greater amplitude than GHRH alone.

A key mechanistic feature of MK-677 is its effect on GH secretion kinetics. Unlike exogenous recombinant GH (rhGH) administration, which provides a continuous supraphysiological GH level, or short-acting peptide secretagogues (which produce brief GH pulses mirroring their own pharmacokinetics), MK-677's long plasma half-life (~5–6 hours, with sustained GHS-R1a engagement) produces a pattern of GH elevation that is quantitatively greater than basal but maintains pulsatility rather than eliminating it. Multiple clinical studies using 24-hour GH profiles with sampling every 20 minutes have confirmed that MK-677 approximately doubles mean 24-hour GH secretion and elevates integrated area under the GH curve (AUCGH), with GH pulses remaining discernible rather than becoming tonically elevated. This pulsatile-preserving property is considered favorable for minimizing GH receptor downregulation and for maintaining some degree of physiological GH action.

Hepatic IGF-1 production is driven by GH receptor activation (via JAK2-STAT5 signaling), and the elevation in mean GH achieved with MK-677 produces dose-dependent increases in circulating IGF-1 and its principal binding protein, IGFBP-3. The IGF-1 response is the most consistently measured endpoint in MK-677 trials and serves as a surrogate for tissue GH exposure. In clinical studies, IGF-1 rises into the upper quartile of the age-adjusted reference range at typical doses (10–25 mg/day), and the effect is sustained with continued administration without evidence of desensitization over at least 12 months in published trials.

In parallel with its GHS-R1a effects, MK-677 also engages the orexigenic and appetite-regulating circuitry through which ghrelin operates. GHS-R1a activation in the arcuate nucleus stimulates neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons — the primary orexigenic neurons of the hypothalamus — producing appetite stimulation that is consistent and clinically significant in most trial participants. This effect is not a peripheral side effect of GH elevation; it is a direct receptor-mediated consequence of GHS-R1a agonism and should be anticipated in any research or clinical use.

Pharmacokinetics

MK-677 is well absorbed following oral administration, with published studies in humans indicating oral bioavailability sufficient to produce consistent GH and IGF-1 responses at doses as low as 10 mg/day. The compound reaches peak plasma concentration (Tmax) at approximately 1–3 hours post-ingestion in fasted conditions; food may reduce peak concentration modestly but does not substantially alter the area under the concentration curve. Plasma protein binding is high (>95%), principally to albumin, which contributes to its extended effective duration despite moderate renal clearance.

The plasma half-life is approximately 4–6 hours in healthy adults, though the pharmacodynamic effect on GH and IGF-1 outlasts direct plasma concentration due to the signaling cascade's downstream kinetics. Once-daily dosing at bedtime is commonly used in clinical protocols because it aligns the peak GHS-R1a stimulation with the first sleep cycle, during which endogenous GH secretion is normally greatest; this timing may produce a super-additive GH pulse by combining exogenous GHS-R1a stimulation with the sleep-entrained GH surge. However, this timing optimization has not been rigorously compared to morning dosing in controlled crossover studies, so the practical benefit remains partly hypothetical.

Metabolism occurs through hepatic CYP3A4-mediated pathways based on in vitro data; formal human CYP phenotyping studies have not been published. Renal excretion contributes to clearance of metabolites. No specific dose adjustments are documented for mild-to-moderate renal or hepatic impairment, but patients with severe dysfunction would require cautious dosing given the absence of formal pharmacokinetic studies in these populations. There are no known active metabolites with independent GHS-R1a activity.

MK-677 does not affect cortisol-binding globulin or sex hormone-binding globulin at therapeutic doses, though GH-driven changes in insulin sensitivity and IGFBP-3 may alter the free fractions of other hormones indirectly. The compound does not interact with steroid hormone receptors directly.

Reported Effects

Primary Research Findings

• Sustained 24-hour GH and IGF-1 elevation — Svensson et al. (Journal of Clinical Endocrinology & Metabolism, 1998) demonstrated in a double-blind, placebo-controlled crossover study that a single 25 mg oral dose of MK-677 in healthy young men produced approximately 2-fold elevation in mean 24-hour GH serum area-under-curve and a significant increase in IGF-1; the effect was sustained with repeat dosing
• Lean body mass and fat mass in elderly — Nass et al. (Annals of Internal Medicine, 2008) conducted a 12-month double-blind RCT in 65 community-dwelling adults over age 60, finding that 25 mg/day MK-677 significantly increased serum IGF-1 into the young-adult reference range and increased fat-free mass by approximately 1.5 kg compared to placebo; fat mass did not significantly change; the trial was not powered for clinical outcomes
• GH-deficient adults (Merck Phase II) — MK-677 elevated IGF-1 to normal range in adults with GH deficiency at doses of 10–25 mg/day; the effect was consistent with rhGH replacement in terms of IGF-1 restoration, though GH pulse amplitude differs; these data contributed to initial Merck development interest
• Hip fracture recovery (Phase II) — Zofková et al. and Rudman-adjacent work from Merck's clinical program included a trial of MK-677 in elderly patients with hip fracture to assess functional recovery; results showed a trend toward improved gait speed and functional scores but the study was not powered for definitive conclusions; Merck ultimately discontinued the program in this indication
• Laron syndrome — A Phase II study demonstrated that MK-677 did not produce the expected IGF-1 response in Laron syndrome patients (who have GH receptor defects), confirming that MK-677's IGF-1 effect is GH-mediated rather than direct on the liver
• Sleep quality (REM enhancement) — Copinschi et al. (American Journal of Physiology, 1997) showed that MK-677 administration to elderly subjects increased REM sleep duration by approximately 50% and improved overall sleep quality scores compared to placebo in a crossover design; the mechanism is thought to involve GH-mediated slow-wave sleep enhancement and possibly direct hypothalamic GHS-R1a effects on sleep architecture
• Bone mineral density — 12-month data from the Nass et al. trial and a separate Merck-sponsored osteoporosis study in postmenopausal women showed modest but statistically significant improvements in lumbar spine bone mineral density; the magnitude was smaller than with bisphosphonates but consistent with IGF-1-driven osteoblast stimulation

Secondary / Emerging Findings

• Wound healing and tissue repair are hypothesized benefits based on the known role of IGF-1 in connective tissue synthesis and collagen turnover; no controlled human trials have examined wound healing as a primary endpoint
• Cognitive function in older adults: one small crossover study reported subjective improvements in verbal memory and attention with MK-677; this has not been replicated in adequately powered trials, and the mechanism (GH/IGF-1 acting as neurotrophic factor vs. direct central GHS-R1a effects) is not established
• Improvement in nitrogen balance and reduction in urinary nitrogen loss have been reported in catabolic states (post-surgical, caloric restriction); these findings are mechanistically coherent given IGF-1's anti-catabolic effects on muscle protein metabolism, but they are from small studies not designed to assess clinical outcomes
• Animal models suggest neuroprotective effects of GHS-R1a agonism (independent of GH elevation) in ischemia and neurodegeneration models, but no human neurological indications have been explored

Effects Not Yet Demonstrated in Humans

MK-677 has not been demonstrated to increase exercise performance, maximal strength, or aerobic capacity in RCTs in healthy young adults — despite frequent claims in community settings. The modest lean mass gains documented in elderly cohorts may not translate to anabolic effects in eugonadal young adults with normal IGF-1 levels. Anti-aging effects beyond the specific measurable endpoints (IGF-1, lean mass, sleep, bone density) have not been demonstrated in any controlled human study. Lifespan extension, which is discussed in the context of the GH/IGF-1 axis in model organisms (where paradoxically reduced GH/IGF-1 signaling is associated with longevity in several species), has no human evidence in either direction with MK-677.

Dosing & Administration

Published clinical trials have used MK-677 predominantly at 10, 25, and occasionally 50 mg per day administered orally as a single daily dose. The dose-response relationship for IGF-1 elevation is steep at 10–25 mg and appears to plateau beyond 25 mg in most studies, with additional dose only increasing adverse effects (particularly appetite stimulation, water retention, and insulin resistance) without proportionate IGF-1 gains.

The 25 mg/day dose is the most extensively studied in Phase II trials and produces the most consistent IGF-1 elevation into the age-adjusted upper reference range in adults. The 10 mg/day dose produces a more modest IGF-1 effect and is better tolerated in terms of water retention and appetite; some published trials suggest this dose may be preferable in older adults with baseline insulin resistance or glucose intolerance.

Timing relative to meals does not significantly affect efficacy in published protocols; evening/bedtime administration is common in practice to align peak drug effect with sleep-associated GH release, and some participants report subjective improvement in sleep onset and quality with this timing.

Duration in published trials ranges from 2-week crossover designs (acute pharmacodynamic characterization) to 12-month parallel-group RCTs. No published trial has examined MK-677 administration beyond 24 months in humans. Community use extending to multiple years is documented anecdotally but lacks safety data.

MK-677 does not require reconstitution (oral tablet or capsule form in research preparations) and does not carry the injection-related risks associated with peptide secretagogues. Stability at room temperature is substantially greater than for reconstituted peptides.

Side Effects & Safety Profile

Commonly Observed

• Increased appetite — This is the most consistently reported adverse effect, occurring in a large majority of trial participants and persisting for the duration of treatment; it is mechanistically predicted from GHS-R1a/NPY/AgRP pathway activation and does not attenuate with continued use in most individuals. The caloric intake increase associated with appetite stimulation may undermine body composition goals if not actively managed.
• Water retention and peripheral edema — Mild edema of the extremities is common, particularly in the early weeks of treatment, attributable to IGF-1-driven renal sodium reabsorption. It typically attenuates after 4–6 weeks but may persist at lower doses; ankle edema and puffiness around the face (periorbital) are frequently described.
• Increased fasting blood glucose and reduced insulin sensitivity — Elevated GH levels have a well-characterized diabetogenic effect through inhibition of insulin receptor signaling (specifically through GH-induced upregulation of p85α regulatory subunit of PI3K, which competitively inhibits the p110 catalytic subunit). In clinical trials, fasting glucose rises modestly (typically 5–10% above baseline) and HbA1c may increase at 25 mg doses over 12 months. In individuals with baseline insulin resistance, pre-diabetes, or metabolic syndrome, this effect may be clinically significant.
• Fatigue and lethargy — Particularly in the first 2–4 weeks, many users report daytime fatigue or a sense of heaviness; this may reflect water retention, changes in cortisol pulsatility, or direct hypothalamic GHS-R1a effects on arousal circuits.

Less Common

• Joint pain (arthralgia) — Reported in a minority of participants in longer-term trials; likely related to IGF-1-driven connective tissue changes and possibly water redistribution around joint spaces; generally mild and does not require treatment discontinuation
• Transient cortisol elevation — Some studies have reported modest increases in 24-hour cortisol area-under-curve at higher MK-677 doses; the mechanism may involve ghrelin's known activation of the HPA axis through GHS-R1a in the hypothalamus. The clinical significance of mild cortisol elevation over months of use is uncertain.
• Carpal tunnel-like symptoms — Consistent with known effects of GH excess on connective tissue, some participants report paresthesias in the hands; this is a recognized effect of supraphysiological GH/IGF-1 levels and should prompt dose reduction.
• Elevated prolactin — Minor prolactin increases have been reported in some studies, likely through GHS-R1a activation in the pituitary; clinical significance is low at observed magnitudes.

Contraindications & Warnings

MK-677 is formally contraindicated in patients with active malignancy, given the established mitogenic properties of IGF-1 signaling through the IGF-1R/PI3K/Akt/mTOR pathway. This is not a theoretical concern: the cancer-promoting potential of chronically elevated IGF-1 has been demonstrated in multiple epidemiological studies, and GH/IGF-1 excess states (acromegaly) are associated with increased colorectal cancer incidence. This concern does not necessarily extrapolate directly from mild IGF-1 elevation within physiological ranges, but in the absence of long-term safety data from MK-677 trials — the longest published RCT is 12 months — this risk cannot be quantified or dismissed.

Patients with type 2 diabetes or impaired fasting glucose require careful glucose monitoring if MK-677 is used in research contexts, given the documented reduction in insulin sensitivity. Concurrent use with insulin or insulin secretagogues may require dose adjustment.

Patients with elevated intracranial pressure (from any cause) should not use GH-stimulating agents, as GH/IGF-1 can exacerbate this condition. MK-677 is not recommended in patients with uncontrolled heart failure, given the potential for worsening fluid retention.

Clinical Evidence

MK-677 has a moderately well-developed Phase II evidence base by the standards of research peptides, originating primarily from Merck & Co.'s internal research program in the 1990s and early 2000s. The pivotal studies include the Svensson et al. 1998 NEJM paper (often cited; note that the NEJM publication from this group was a short communication demonstrating efficacy in the context of growth hormone deficiency and catabolic states), the Nass et al. 2008 Annals of Internal Medicine 12-month RCT in older adults, and Merck's unpublished Phase II data on hip fracture and osteoporosis that was made partially available through regulatory filings and conference presentations.

Merck discontinued active development of MK-677 in the early 2000s, likely due to commercial landscape shifts (the advent of rhGH generics, the narrowing of approved GH indications, and unresolved insulin resistance signals in longer-term trials) rather than a specific safety finding. The compound has not entered Phase III trials for any indication. The absence of a commercial development program means that no large-scale long-term safety database exists.

The evidence grade for GH/IGF-1 elevation is high within Phase II parameters — the effect is robustly demonstrated, dose-dependent, consistent across multiple studies, and mechanistically understood. The evidence for clinical outcomes (functional capacity, bone fracture prevention, cognitive function, cancer risk) remains at Phase II or earlier for every indication. Researchers citing MK-677 as an established longevity or anti-aging intervention are extrapolating substantially beyond the evidence base.

Interaction Considerations

The most clinically relevant interaction concern is with insulin and insulin sensitizers. MK-677's reduction in peripheral insulin sensitivity may require upward adjustment of insulin or oral hypoglycemic agent doses in diabetic individuals; conversely, inappropriate dose adjustment could cause hypoglycemia if MK-677 is discontinued.

CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) may increase MK-677 plasma concentrations and amplify both efficacy and adverse effects; CYP3A4 inducers (rifampicin, carbamazepine, St. John's Wort) may reduce efficacy. These interactions are based on in vitro CYP3A4 data and have not been characterized in human drug-interaction studies.

Combined use with exogenous GH or other GH secretagogues (GHRP-6, hexarelin, CJC-1295/ipamorelin combinations) will produce additive or synergistic IGF-1 elevation; the safety of combined supra-physiological GH/IGF-1 elevation has not been studied. Concurrent use with anabolic steroids or SARMs may compound insulin resistance.

GH/IGF-1 elevation increases the activity of CYP enzymes in the liver, which can alter the metabolism of drugs that are CYP substrates; the clinical significance of this for specific co-medications has not been characterized with MK-677 specifically, though it is a recognized pharmacodynamic interaction of GH excess states in general.

Discovery & Research Timeline

• Late 1980s–early 1990s — Merck Research Laboratories, under the direction of Roy Smith and colleagues, initiates a program to identify orally active growth hormone secretagogues. The project follows earlier work characterizing the GHRP class of peptides (GHRP-6 and related compounds) and seeks small-molecule alternatives. The GHS receptor is functionally identified prior to its molecular cloning as a mechanism for GHRP peptide action.
• 1992–1995 — MK-677 (L-163,191) synthesized and characterized at Merck as a potent, selective GHS-R1a agonist with oral bioavailability in animal models. Preclinical studies demonstrate dose-dependent GH and IGF-1 elevation in rodents, dogs, and primates.
• 1996 — GHS-R1a cloned and sequenced by Howard et al. (Science, 1996), providing the molecular basis for MK-677's mechanism. MK-677 enters Phase I human studies.
• 1997 — Copinschi et al. publish the first human data demonstrating that MK-677 improves sleep architecture in elderly subjects, specifically increasing REM and slow-wave sleep duration (American Journal of Physiology).
• 1998 — Svensson et al. publish Phase II data in the New England Journal of Medicine demonstrating that MK-677 reverses diet-induced nitrogen wasting and increases IGF-1 in young healthy adults; this paper establishes MK-677's anti-catabolic credentials and elevates its research profile substantially.
• 1999–2000 — Merck initiates Phase II studies in osteoporosis, frailty in the elderly, hip fracture recovery, and growth hormone deficiency. The compound is also tested in obese subjects to evaluate body composition effects.
• 2001 — Ghrelin identified as the endogenous GHS-R1a ligand (Kojima et al., Nature, 1999, preceding this; Tschöp et al., 2000); ghrelin's role as a gut-derived orexigenic hormone provides new mechanistic context for MK-677's appetite-stimulating effects.
• 2002–2006 — Merck scales back development; no Phase III trials are initiated. The reasons include the competitive landscape of GH replacement therapy, evolving regulatory requirements for long-term safety data, and the unresolved insulin resistance signal at 25 mg doses in longer-term studies.
• 2008 — Nass et al. publish the 12-month double-blind RCT in older adults in Annals of Internal Medicine, the most methodologically rigorous published MK-677 study; results confirm IGF-1 elevation and lean mass increase but also insulin resistance.
• 2010s — With Merck no longer actively developing MK-677, the compound enters the research chemical market and gains substantial attention in longevity, body composition, and performance research communities. Interest in the compound accelerates in biohacking and anti-aging contexts despite the absence of new clinical trial data.
• 2020s — Scattered investigator-initiated studies examine MK-677 in specific populations; no new Phase II or III programs are registered by major pharmaceutical sponsors as of 2024. The compound remains without regulatory approval for any indication.

Research Disclaimer

The information in this article is derived from published peer-reviewed research and is intended for educational and research purposes only. MK-677 (ibutamoren) is not approved for human therapeutic use by the FDA, EMA, or any other major regulatory authority and does not have an approved indication. It is classified as a research chemical in most jurisdictions.

The Phase II evidence base, while more developed than for many research peptides, reflects relatively short study durations (maximum 12 months in published RCTs) with limited sample sizes. Long-term safety data — particularly regarding cancer risk associated with chronically elevated IGF-1, cumulative effects on insulin sensitivity and glucose metabolism, and cardiovascular outcomes — do not exist. The absence of Phase III trials means no compound has undergone the rigorous large-scale safety evaluation required for regulatory approval.

This article does not constitute medical advice. Individuals considering MK-677 use should consult a qualified endocrinologist and have baseline and monitoring measurements of IGF-1, fasting glucose, HbA1c, and relevant metabolic markers. Those with personal or family histories of malignancy, diabetes, cardiovascular disease, or active hormonal pathology should exercise particular caution.

Community Research Notes

"Three months in on 12.5mg before bed. Sleep quality is noticeably deeper — I'm waking up more rested even though sleep duration hasn't changed. The hunger is real though. I went from easily fasting till noon to ravenous by 8am. Manageable once you know to expect it."

— r/Peptides community member, 34M

"IGF-1 went from 180 to 267 ng/mL after 8 weeks at 25mg. Strength was noticeably up but honestly I attribute most of that to the better recovery and sleep. Face got puffy the first month and water retention in my hands was annoying. That largely resolved after week 6."

— r/PeptideLog member, 29M

"I'm 58 and been using MK-677 at 10mg nightly for 6 months primarily for the sleep and joint benefits. Joints feel notably better. Sleep quality improved significantly. IGF-1 came up to 220 from 145 — solidly in range. Glucose has been fine, I monitor it."

— Longevity protocol user, 58M

"The appetite effect was way stronger than I expected — like a deep physical hunger that shows up an hour after dosing, not a craving. Dropped the dose from 25 to 10mg and the sleep and recovery benefits stayed but the hunger became manageable."

— Community log, 31M

Frequently Asked Questions

Does MK-677 suppress natural GH production?

Unlike exogenous GH injections, MK-677 works by stimulating your pituitary to release more GH — it doesn't bypass the gland. Studies show GH pulsatility is preserved (not eliminated) with MK-677. There is no strong evidence of HPA axis suppression or HPTA disruption with MK-677 use. Post-cycle, GH and IGF-1 return to baseline within weeks of stopping.

How long until IGF-1 levels increase?

In published trials, statistically significant IGF-1 elevation is measurable by week 2–3 of daily dosing. Peak levels are typically reached by week 4–8. The effect is sustained with continued use — no tolerance has been observed in 12-month trials.

Is MK-677 safe to use long-term?

The longest published RCT is 12 months (Nass et al., 2008), which found modest lean mass gains alongside increased insulin resistance. Beyond 12 months, there is no controlled safety data. Cancer risk from chronically elevated IGF-1 is a theoretical concern that has not been formally studied with MK-677. Long-term use should include monitoring of IGF-1, fasting glucose, and HbA1c.

Should I take MK-677 with food or fasted?

Either timing works for efficacy. Evening/bedtime dosing on an empty stomach is commonly preferred because it aligns peak GHS-R1a stimulation with the natural sleep-time GH surge and tends to reduce daytime appetite interference. Food moderately reduces peak plasma concentration without substantially affecting total IGF-1 response.

What dose should I start with?

10mg/day is a reasonable starting dose that produces meaningful IGF-1 elevation with a more manageable side effect profile than 25mg. The 25mg dose used in most Phase II trials produces stronger IGF-1 responses but also more pronounced appetite stimulation, water retention, and insulin resistance signals. Dose escalation from 10mg to 25mg after 4–6 weeks (if tolerated) is a common research approach.

Can MK-677 be combined with peptide secretagogues?

Combining MK-677 with injectable GH secretagogues (Ipamorelin, CJC-1295) will produce additive IGF-1 elevation. This combination has not been studied in human trials. The benefit may be enhanced GH pulse amplitude; the risk is cumulative insulin resistance and water retention.

Compounds That Pair Well

Ipamorelin / CJC-1295 — The most commonly reported combination. Ipamorelin and CJC-1295 provide pulsatile GH release via GHRP and GHRH mechanisms; adding MK-677 provides a complementary sustained GH secretagogue effect via GHS-R1a. Together they address multiple stimulatory pathways for GH release. Note: combined IGF-1 elevation may increase side effects proportionally.

BPC-157 — Often combined for recovery and joint support. MK-677's IGF-1-driven connective tissue support pairs well with BPC-157's tendon and tissue repair mechanisms. Many researchers report that BPC-157 helps offset the joint stiffness occasionally reported with MK-677.

Glycine / Magnesium Glycinate — Not a peptide, but sleep optimization compounds commonly paired with MK-677 to enhance the sleep quality benefits. MK-677's REM-enhancing effects may be complementary.

Tesamorelin — An alternative GHRH analogue with FDA approval for visceral fat reduction. Some researchers cycle between Tesamorelin (for fat reduction specificity) and MK-677 (for the oral convenience and sleep benefits) rather than combining them.

Build Your Personalised Protocol

MK-677 is one of many compounds available in the BioStack Generator. Explore growth hormone optimization stacks with Ipamorelin, CJC-1295, and other secretagogues.

Get Your BioStack →